INO-B002

N/A

Report date: 2026/03/19 16:58:12

Base Information

Drug NameINO-B002
Drug Alias NameDNA-encoded bi-specific T cell engager targeting HER2 (Inovio Pharmaceuticals/Wistar Institute)HER2-dBiTEdBTA-HER2CD3anti-CD3/anti-HER2 bispecific T-cell engager (Inovio Pharmaceuticals/Wistar Institute)anti-CD3/anti-HER2 dBiTE (Inovio Pharmaceuticals/Wistar Institute) +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInovio Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesInovio Pharmaceuticals IncThe Wistar Institute Of Anatomy And Biology
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursOvarian Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A